Airway diseases
Respiratory critical care
Respiratory infections
Oral presentation
Clinical trials in COPD: new results
Methods :
General respiratory patient care
Chairs
M. Vukoja
Sremska Kamenica
(Republic of Serbia)
14:45
Late Breaking Abstract - Azithromycin for acute COPD exacerbations requiring hospitalization – the BACE trial results
W. Janssens(Leuven, Belgium)
COI
1
15:00
COPD exacerbations in the phase 3 revefenacin clinical trial program
J. Donohue(Chapel Hill, United States)
COI
2
15:15
Pharmacodynamic and pharmacokinetic results after repeated doses of AZD8871 in COPD patients
I. Psallidas(London, United Kingdom)
COI
3
15:30
Early Clinically Important Improvement (ECII) and exacerbation outcomes in the FLAME study
K. Kostikas(Ioannina, Greece)
COI
4
15:45
Single inhaler triple therapy in patients with COPD: response rates in health-related quality of life in the IMPACT Trial
M. Tabberer(Uxbridge (Middlesex), United Kingdom)
COI
5
16:00
Reduction in fatal events with extrafine inhaled corticosteroid (ICS)-containing medications: results of stratified safety pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies.
L. Fabbri(Modena, Italy)
COI
6
16:15
Economic and quality of life consequences of clinically important deterioration in patients with COPD: results from the TORCH study
A. Ismaila(Malvern, United States)
COI
7
16:30
KRONOS: 24-week study of triple fixed-dose combination budesonide/glycopyrronium/formoterol (BGF) MDI via co-suspension delivery technology vs glycopyrronium/formoterol (GFF) MDI, budesonide/formoterol (BFF) MDI and BFF inhalation powder in COPD
G. Ferguson(Farmington Hills, United States)
COI
8
. . .
